BioCryst Pharmaceuticals Reports Q1 Earnings with Strong ORLADEYO Performance
BioCryst Pharmaceuticals reported $148.3 million in first-quarter net revenue from its HAE therapy, ORLADEYO, a 21% year-over-year increase excluding the European divestiture impact. The company also highlighted progress on clinical trials and cash reserves despite an R&D charge related to asset acquisition.
Tickers: $BCRX
Topics: hereditary_angioedema_treatment pharmaceutical pipeline_progress